Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement

References

• Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome – risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157–62.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560–70.
   PubMed Web of Science ®Google Scholar
• Stranne J, Damber JE, Fall M, Hammarsten J, Knutson T, Peeker R. One-third of the Swedish male population over 50 years of age suffers from lower urinary tract symptoms. Scand J Urol Nephrol 2009;43:199–205.
   PubMed Web of Science ®Google Scholar
• Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract 2007;61:1437–45.
   PubMedGoogle Scholar
• Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45–103 years. Eur Urol 2010;58:149–56.
   PubMed Web of Science ®Google Scholar
• Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006;68:804–9.
   PubMed Web of Science ®Google Scholar
• McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174:1327–433.
   PubMed Web of Science ®Google Scholar
• Ullrich PM, Lutgendorf SK, Kreder KJ. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology 2007;70:487–91. discussion 91–2.
   PubMed Web of Science ®Google Scholar
• Björntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997;13:795–803.
   PubMed Web of Science ®Google Scholar
• Björntorp P, Rosmond R. The metabolic syndrome – a neuroendocrine disorder? Br J Nutr 2000;83:S49–57.
   PubMed Web of Science ®Google Scholar
• Haghsheno MA, Mellstrom D, Behre CJ, Damber JE, Johansson H, Karlsson M, et al. Low 25-OH vitamin D level is associated with benign prostatic enlargement (BPE). J Urol 2013;190:608–14.
   Google Scholar
• Johansson H, Oden A, Kanis J, McCloskey E, Lorentzon M, Ljunggren O, et al. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int 2012;23:991–9.
   PubMed Web of Science ®Google Scholar
• Mellstrom D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Oden A, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008;23:1552–60.
   PubMed Web of Science ®Google Scholar
• Paul-Savoie E, Potvin S, Daigle K, Normand E, Corbin JF, Gagnon R, et al. A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin J Pain 2011;27:529–34.
   PubMed Web of Science ®Google Scholar
• Wong SY, Hong A, Leung J, Kwok T, Leung PC, Woo J. Lower urinary tract symptoms and depressive symptoms in elderly men. J Affect Disord 2006;96:83–8.
   PubMed Web of Science ®Google Scholar
• Rom M, Schatzl G, Swietek N, Rucklinger E, Kratzik C. Lower urinary tract symptoms and depression. BJU Int 2012;110:E918–21.
   PubMed Web of Science ®Google Scholar
• Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol 1999;162:82–4.
   PubMed Web of Science ®Google Scholar
• Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin 2013;29:279–87.
   PubMed Web of Science ®Google Scholar
• Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 2007;51:67–74.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, Cakmak O, Ozdemir I, Bolukbasi A, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29–34.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005;29:310–16.
   PubMed Web of Science ®Google Scholar
• Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus – a nitric oxide-dependent phenomenon. Br J Pharmacol 1999;128:1804–12.
   PubMed Web of Science ®Google Scholar
• Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2013;189:S107–14. discussion S15–6.
   PubMed Web of Science ®Google Scholar
• Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010;20:7–12.
   PubMed Web of Science ®Google Scholar
• Chang IH, Oh SY, Kim SC. A possible relationship between testosterone and lower urinary tract symptoms in men. J Urol 2009;182:215–20.
   Google Scholar
• Ehren I, Iversen H, Jansson O, Adolfsson J, Wiklund NP. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 1994;44:683–7.
   Google Scholar
• Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009;41:7–13.
   PubMed Web of Science ®Google Scholar
• Uckert S, Waldkirch ES, Merseburger AS, Kuczyk MA, Oelke M, Hedlund P. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. World J Urol 2013;9:9.
   Google Scholar
• Johansson H, Oden A, Lerner UH, Jutberger H, Lorentzon M, Barrett-Connor E, et al. High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res 2012;27:1390–6.
   PubMed Web of Science ®Google Scholar
• Lindberg S, Mogelvang R, Pedersen SH, Bjerre M, Frystyk J, Flyvbjerg A, et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013;31:043.
   Google Scholar